HeartBeam Wins Patent for 12-Lead ECG Smartwatch Monitor

HeartBeam, a company that’s developed the first and only 3D-vector electrocardiogram (VECG) platform to detect heart attacks, announced that the U.S. Patent and Trademark Office allowed its patent for a 12-lead ECG smartwatch-based monitor to spot heart attacks and complex arrhythmias.
 
Currently available wearable technologies aren’t capable of providing a 12-lead ECG to detect heart attacks, monitor complex arrhythmias, or monitor other cardiac disorders. According to HeartBeam, its latest patent further boosts the company’s “anytime, anywhere” capabilities.
 
“The breakthrough inventions protected by this patent enable our proprietary 3D ECG technology to be built into a smartwatch, eliminating the need for a dedicated ECG device while offering a 12-lead ECG capability enabling heart attack and complex arrhythmia detection,” HeartBeam CEO and founder Branislav Vajdic, Ph.D. told the press. “This patent may prove to be one of the most valuable patents in our rich and growing patent portfolio and, together with our 12-lead ECG patch patent, I believe, will have a disruptive effect on these existing multi-billion dollar fast-growing markets.”
 
HeartBeam is presently focused on development, clinical, and regulatory activities for its HeartBeam AIMI and AIMIGo systems but aims to continue advancing its 12-lead 3D vector ECG tech.